P53结合蛋白1在宫颈鳞癌中的表达及其临床意义

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (754 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：探讨P53结合蛋白1（53BP1）在宫颈鳞癌组织中的表达情况及其与临床分期、分化程度、淋巴结转移以及病灶大小的关系。方法：选取2010年5月至2011年8月期间在温州医科大学附属第一医院妇科收治的临床资料完整的52例宫颈鳞癌、30例宫颈上皮内瘤变（CIN）和20例正常宫颈组织，采用实时荧光定量PCR技术检测53BP1 mRNA的表达水平，并对其表达水平与临床病理特征的关系进行统计学分析。结果：宫颈鳞癌组织中53BP1 mRNA相对表达水平明显低于正常组织，差异具有统计学意义（P＜0.05）。宫颈鳞癌中高分化组中53BP1 mRNA相对表达水平明显高于宫颈鳞癌低分化组，差异具有统计学意义（P＜0.05）。宫颈鳞癌无淋巴结转移组中53BP1 mRNA相对表达水平明显高于宫颈鳞癌淋巴结转移组，差异具有统计学意义（P＜0.05）。宫颈鳞癌FIGO I期组和FIGOⅡ期组以及宫颈鳞癌大病灶组和小病灶组间53BP1 mRNA相对表达水平比较，差异均无统计学意义（P＞0.05）。结论：53BP1在宫颈鳞癌组织中表达减低，与分化程度、淋巴结转移有关，与病灶大小、临床分期无明显相关。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	诸海燕1
	金纬纬2
	胡燕1
	郑飞云1

关键词 ：宫颈肿瘤, 实时荧光定量, 聚合酶链反应, P53结合蛋白1

Abstract：Objective: To explore the expression of P53-binding protein 1 (53BP1) in the tissue of cervical squamous carcinoma and relationship among their clinical stages, the degree of differentiation, lesion of lymph node metastasis and size. Methods: Fifty-two cases of cervical squamous carcinoma, 30 cases of cervical intraepithelial neoplasia (CIN) and 20 cases of normal cervical tissue were selected. Then the real-time fluorescent quantitative PCR was adopted for the detection of 53BP1 mRNA expression, and the statistical analysis of its expression and its clinical pathological characteristics were complemented as well. Results: 53BP1 mRNA in cervical squamous carcinoma relative expression levels were significantly lower than that in normal tissue, and the difference was statistically significant (P<0.05). 53BP1 mRNA expression in the differentiation of cervical squamous carcinoma in higher group level was significantly higher than that in the group of poorly differentiated carcinoma of the cervix, and the difference was statistically significant (P<0.05). 53BP1 mRNA in cervical lymph node metastasis-free group relative expression levels were significantly higher than that in the cervical lymph node metastasis group, and the differences were statistically significant (P<0.05). Compared the expression levels in FIGO I group of cervical cancer and cervical carcinoma FIGO II group, and focus-group and small lesions 53BP1 mRNA, the difference was not statistically significant (P>0.05). Conclusion: 53BP1 expression in cervical squamous cancer reduction is associated with the degree of differentiation, lymphatic metastasis, and lesion size, while it is not significantly related in clinical stages.

Key words： uterine cervical neoplasms real-time fluorogentic quantitative PCR 53BP1

收稿日期: 2013-09-08

基金资助:温州市科技计划基金资助项目（Y20090261）

通讯作者: 胡燕，主任医师，Email：627830566@qq.com。

作者简介: 诸海燕（1978-），女，浙江温州人，主治医师，硕士。

链接本文:

https://xb.wmu.edu.cn/CN/ 或 https://xb.wmu.edu.cn/CN/Y2014/V44/I2/134

[1] Bartkova J, Horejsi Z, Sehested M, et al. DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours[J]. Oncogene, 2007, 26(53):7414-7422.

[2] Lai TC, Chow KC, Lin TY, et al. Expression of 53BP1 as a cisplatin-resistant marker in patients with lung adenocarcinomas[J]. Oncol Rep, 2011, 24(2): 321-328.

[3] Naruke Y, Nakashima M, Suzuki K, et al. Alteration of p53-binding protein 1 expression during skin carcinogenesis: association with genomic instability[J]. Cancer Sci, 2008, 99 (5): 946-951.

[4] Iwabuchi K, Li B, Massa HF, et al. Stimulation of p53-mediated transcriptional activation by the p53-binding proteins, 53BP1 and 53BP2[J]. J Biol Chem, 1998, 273(40): 26061-26068.

[5] Nakashima M, Suzuki K, Meirmanov S, et al. Foci formation of P53-binding protein 1 in thyroid tumors: activation of genomic instability during thyroid carcinogenesis[J]. Int J Cancer, 2008, 122(5): 1082-1088.

[6] Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions[J]. Nature, 2005, 434(7035):907-913.

[7] Nuciforo PG, Luise C, Capra M, et al. Complex engagement of DNA damage response pathways in human cancer and in lung tumor progression[J]. Carcinogenesis, 2007, 28(10):2082-2088.

[8] 杜然, 张惠箴, 陈杰, 等. 53BP1蛋白表达缺失与前列腺腺癌临床病理的关系[J]. 临床与实验病理学杂志, 2011, 27(1): 44-47.

[9] Ward IM, Difilippantonio S, Minn K, et al. 53BP1 cooperates with p53 and functions as a haploinsufficient tumor suppressor in mice[J]. Mol Cell Biol,2005, 25(22): 10079-10086.

[10] Hong S, Li X, Zhao Y, et al. 53BP1 suppresses tumor growth and promotes susceptibility to apoptosis of ovarian cancer cells through modulation of the Akt pathway[J]. Oncol Rep,2012, 27(4): 1251-1257.

[11] Matsuda K, Miura S, Kurashige T, et al. Significance of p53-binding protein 1 nuclear foci in uterine cervical lesions: endogenous DNA double strand breaks and genomic instability during carcinogenesis[J]. Histopathology, 2011, 59(3):441-451.

[12] 唐卓葳, 吴诚义. 53BP1在乳腺癌中的表达及其意义[J]. 中国普通外科杂志, 2009, 18(5): 518-521.

[13] Bouwman P, Aly A, Escandell JM, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers[J]. Nat Struct Mol Biol, 2010,17(6): 688-695.